亚洲 · 区域市场 · Business Standard
Emcure Pharma surges 10%, stock hits new high on strong outlook
Analysts at Jefferies remain positive on Emcure Pharma's near- to mid-term outlook, supported by multiple growth drivers and operating-leverage benefits.
在 Business Standard 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.business-standard.com)
